Before the development, during the past decade, of effective chemotherapy for malignant germ-cell tumours, the majority of patients with advanced disease died and their survival time was short. In contrast, many patients in this previously hopeless category are now curable, although two major problems remain, the toxicity of therapy and the poor prognosis of patients with bulky disseminated disease. Approximately 70% of patients with advanced non-seminomatous germ-cell testicular tumours are rendered disease-free with cis-platin, vinblastine and bleomycin (PVB) (Einhorn & Donohue, 1977; Einhorn & Williams, 1980) . However, the outcome of treatment is influenced by the size of metastases so that, whereas patients with small volume disease have an excellent prognosis, the association of bulky abdominal and thoracic tumour significantly reduces the chance of cure. Furthermore, PVB is associated with considerable morbidity, particularly myelosuppression, and a small percentage of patients die from chemotherapy-related complications. Although toxicity may not be a primary concern in high risk patients with bulky metastases, it is important in patients with good prognosis where better-tolerated combinations may be developed without loss of therapeutic effectiveness. Patients who have been irradiated tolerate PVB poorly and the risk of severe bone marrow depression is high (Einhorn & Williams, 1980) . Furthermore, our own experience suggested that the use of vinblastine was associated with a risk of gastro-intestinal damage in previously irradiated patients. For these reasons, in 1979, vinblastine in the PVB combination was replaced by etoposide (VP-16-213) a semi-synthetic derivative of podophyllotoxin which has shown activity as a single agent in testicular non-seminoma patients relapsing after first line chemotherapy (Table I) (Cavalli et al., 1981; Fitzharris et al., 1980; Newlands & Bagshawe, 1977; Williams et al., 1980 Williams et al., , 1982 Varini & Cavalli, 1982; Bremer et al., 1982) . Initially, the combination of bleomycin, etoposide and cis-platin (BEP) was used only in patients relapsing after radiotherapy but encouraged by preliminary experience, BEP was introduced as first line treatment for patients with Stage II, III & IV disease in 1980. This report describes the results obtained with BEP in the management of 43 patients with metastatic germ-cell tumours, 36 of whom had nonseminomatous testicular tumours and 7 advanced testicular seminoma. (Peckham, 1981a) was employed: (Peckham, 1981b) .
Of the 43 patients, 9 received 6 cycles of BEP, one patient 5 cycles, one patient 3 cycles of BEP and 3 of EP, 31 four cycles and one patient 2 cycles. Ten patients had elective radiotherapy after chemotherapy and 11 patients came to surgery.
Results
The outcome of treatment of the whole group of 43 patients is shown in Tables II and III (Issell & Crooke, 1979) . As shown in Table  VIII , haematological toxicity was mild and unassociated with major infective episodes after cycles of BEP containing 3 days of etoposide. Toxicity was more severe after S day etoposide cycles; 4 patients required hospitalisation for neutropenic fever and were treated with broad spectrum antibiotics and a 5th patient had proven septicaemia. In addition, 4 patients developed chest infections requiring admission to hospital and one died. One patient developed a lung abcess and another cellulitis. In the previously untreated group the percentage of patients receiving cycles with 3 and S days of etoposide respectively who developed low blood counts was as follows, white count < 1.500 x 103: 3.8% vs 14.5%, platelets < I100,000mm-3: 0% vs 11.3%.
Toxicity was more severe in previously irradiated patients, although there are too few cycles with 3 days of etoposide to allow useful comparison. The percentages of S day etoposide cycles followed by low blood counts in irradiated (38 cycles) and nonirradiated patients (62 cycles) were respectively: white count < 1500mm-3, 21% and 14%; platelets < I100,000mm-3, 26.3% and 11.2%; haemoglobin <IOg I-', 28.9% and 12.9%.
No death occurred in previously untreated patients, although one patient who had had prior irradiation died of a fulminating chest infection complicating bleomycin lung damage.
Epilation was invariable. Nausea and vomiting varied in intensity and duration between patients and from one cycle to another in individual patients. Severe vomiting in one patient was associated with haematemesis. All patients lost weight during treatment and rapid weight gain often with a tendency to exceed pre-treatment weight was a common feature. Numbness, thickening or tenderness of fingers and toes clearance value compared with 4/9 in the previously irradllttd group.
Discussion
The clinical experience summarised in this report shows that BEP is a highly active combination with 25/28 (89.3%) of previously untreated testicular nonseminoma patients alive and disease-free. Since patients who are disease-free one year after starting chemotherapy very rarely relapse (none in the present series) it is probable that these data reflect the cure potential of BEP although larger patient numbers and longer observation times will be necessary to establish this with confidence. No formal comparison with PVB has been undertaken but BEP would appear at least as active; indeed it is encouraging that 15/19 previously untreated testicular non-seminoma patients with bulky metastases are disease-free. BEP was developed initially to manage patients relapsing after radiotherapy where PVB is extremely hazardous and "analogous to remission induction in acute myeloblastic leukaemia" (Einhorn & Williams, 1980) . Although the toxicity of BEP in irradiated patients is more severe than in untreated patients, in our experience the complications are considerably less than those encountered after PVB. In the initial PVB combination in which vinblastine was used in a dose of 0.4 mg kg-1 per cycle, neutropenia was severe, 35% of patients developed granulocytopenic fever and 12% proven septicaemia (Einhorn & Donohue, 1977; Einhorn & Williams, 1980) . A dose reduction of vinblastine to 0.3 mg kg-1 was associated with less myelosuppression without loss of therapeutic effect. Even so, most patients experienced granulocyte counts of <I000 cu -mm and 15% were treated for granulocytopenic fever (Einhorn & Williams, 1980) . In the present series the incidence of proven or presumed septicaemia was 11.6% (5/43 patients).
The data with BEP containing three days of etoposide indicate that as expected this is less myelosuppressive than BEP with 5 days of etoposide. Although a formal comparison of the toxicity of PVB with 0.3mgkg-' vinblastine and BEP with etoposide days 1-3 has not been completed, we have little doubt having used both regimens that the latter combination is better tolerated both subjectively and objectively. Obviously an important question is whether a dose reduction of etoposide from 120mgm 2 x 5 to 120mgm-2 x 3 with each cycle is associated with a reduction of anti-tumour activity. The present data provide evidence that this is not the case (Table VII) . In the non-seminoma group of previously untreated patients 16 received cycles containing 3 days of etoposide and 12 patients cycles containing 5 days of etoposide. The diseasefree survival rates are 14/16 (87.5%) and 11/12 (91.7%) respectively.
In current protocols all patients, except those with small volume disease (Stages IM, IIA, IIB, IIIA, IIIB, IVALj), are being treated with BEP to obtain more information on the response of high risk patients with bulky abdominal and intrathoracic disease. Following the introduction of BEP as first line chemotherapy for previously unirradiated patients all patients were treated with this combination. The only exclusions being 10 men with advanced bulky presentations (IV L3 H +) who were entered into a multicentre study of bleomycin, etoposide, vinblastine and cis-platin (BEVIP). Patients with small volume disease are being entered into a Phase II study of etoposide and cis-platin (EP) initiated in January 1982.
